PT - JOURNAL ARTICLE AU - Samira Luisa Apostolos-Pereira AU - Lis Campos Ferreira AU - Mateus Boaventura AU - Nise Alessandra de Carvalho Sousa AU - Gabriela Joca Martins AU - José Arthur d'Almeida AU - Milena Pitombeira AU - Lucas Silvestre Mendes AU - Thiago Fukuda AU - Hideraldo Luíz Souza Cabeça AU - Luciano Chaves Rocha AU - Bianca Santos de Oliveira AU - Carla Renata Vieira Stella AU - Enedina Maria Lobato de Oliveira AU - Leizian de Souza Amorim AU - Andréa Ferrari de Castro AU - Antonio Pereira Gomes Neto AU - Guilherme Diogo Silva AU - Lucas Bueno AU - Maria de Morais Machado AU - Rafael Castello Dias-Carneiro AU - Ronaldo Maciel Dias AU - Alvaro Porto Moreira AU - Ana Piccolo AU - Anderson Kuntz Grzesiuk AU - Andre Muniz AU - Caio Diniz Disserol AU - Claudia Ferreira Vasconcelos AU - Damacio Kaimen-Maciel AU - Denise Sisterolli Diniz AU - Elizabeth Comini-Frota AU - Fernando Coronetti Rocha AU - Gutemberg Augusto Cruz dos Santos AU - Yara Dadalti Fragoso AU - Guilherme Sciascia do Olival AU - Heloisa Helena Ruocco AU - Heloise Helena Siqueira AU - Henry Koity Sato AU - José Alexandre Figueiredo, Jr AU - Leandro Cortoni Calia AU - Mario Emilio Teixeira Dourado, Jr AU - Letícia Scolari AU - Herval Ribeiro Soares Neto AU - Luiz Melges AU - Marcus Vinicius Magno Gonçalves AU - Maria Lucia Vellutini Pimentel AU - Marlise de Castro Ribeiro AU - Omar Gurrola Arambula AU - Paulo Diniz da Gama AU - Renata Leite Menon AU - Rodrigo Barbosa Thomaz AU - Rogério de Rizo Morales AU - Silvana Sobreira AU - Suzana Nunes Machado AU - Taysa Gonsalves Jubé Ribeiro AU - Valéria Coelho Santa Rita Pereira AU - Vanessa Maia Costa AU - Adaucto Wanderley da Nóbrega Junior AU - Soniza Vieira Alves-Leon AU - Marilia Mamprim de Morais Perin AU - Eduardo Donadi AU - Tarso Adoni AU - Sidney Gomes AU - Maria Brito Ferreira AU - Dagoberto Callegaro AU - Maria Fernanda Mendes AU - Doralina Brum AU - Felipe von Glehn ED - , TI - Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders AID - 10.1212/NXI.0000000000001060 DP - 2021 Nov 01 TA - Neurology - Neuroimmunology Neuroinflammation PG - e1060 VI - 8 IP - 6 4099 - http://nn.neurology.org/content/8/6/e1060.short 4100 - http://nn.neurology.org/content/8/6/e1060.full SO - Neurol Neuroimmunol Neuroinflamm2021 Nov 01; 8 AB - Background and Objectives To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described.Results Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8–77), with disease onset at 31 years (range 4–69) and disease duration of 6 years (range 0.2–20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection.Discussion Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.AQP4=aquaporin 4; CBA=cell-based assay; CI=confidence interval; COVID-19=coronavirus disease 2019; DMT=disease-modifying therapy; MS=multiple sclerosis; NMOSD=neuromyelitis optica spectrum disorders; OR=odds ratio; pwNMOSD=patients with NMOSD; RT-PCR=reverse transcription-polymerase chain reaction; SARS=severe acute respiratory syndrome